ES2547855T3 - Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria - Google Patents
Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria Download PDFInfo
- Publication number
- ES2547855T3 ES2547855T3 ES07800235.9T ES07800235T ES2547855T3 ES 2547855 T3 ES2547855 T3 ES 2547855T3 ES 07800235 T ES07800235 T ES 07800235T ES 2547855 T3 ES2547855 T3 ES 2547855T3
- Authority
- ES
- Spain
- Prior art keywords
- antigen
- adjuvant
- flu
- doses
- iscomatrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title description 2
- 239000000427 antigen Substances 0.000 abstract description 38
- 102000036639 antigens Human genes 0.000 abstract description 38
- 108091007433 antigens Proteins 0.000 abstract description 38
- 239000002671 adjuvant Substances 0.000 abstract description 25
- 241001465754 Metazoa Species 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 206010022000 influenza Diseases 0.000 description 33
- 238000002649 immunization Methods 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 241001494479 Pecora Species 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 12
- 230000002685 pulmonary effect Effects 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006904796A AU2006904796A0 (en) | 2006-09-01 | Method of Eliciting or Inducing an Immune Response | |
| AU2006904796P | 2006-09-01 | ||
| PCT/AU2007/001277 WO2008025095A1 (en) | 2006-09-01 | 2007-08-31 | Method of eliciting or inducing an immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2547855T3 true ES2547855T3 (es) | 2015-10-09 |
Family
ID=39135429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07800235.9T Active ES2547855T3 (es) | 2006-09-01 | 2007-08-31 | Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9150619B2 (enExample) |
| EP (1) | EP2066341B1 (enExample) |
| JP (1) | JP5265545B2 (enExample) |
| KR (1) | KR20090064412A (enExample) |
| CN (1) | CN101522213A (enExample) |
| AU (1) | AU2007291887B2 (enExample) |
| CA (1) | CA2662164A1 (enExample) |
| DK (1) | DK2066341T3 (enExample) |
| ES (1) | ES2547855T3 (enExample) |
| NZ (1) | NZ575141A (enExample) |
| WO (1) | WO2008025095A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039715D1 (de) * | 1999-11-19 | 2008-09-11 | Csl Ltd | Hcv-impfstoff zusammensetzungen |
| SG185294A1 (en) * | 2007-10-12 | 2012-11-29 | Csl Ltd | Method of eliciting an immune response against pandemic influenza virus |
| EP2501396B1 (en) | 2009-11-18 | 2018-04-25 | Auburn University | Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease |
| KR102146340B1 (ko) * | 2012-03-27 | 2020-08-24 | 배리에이션 바이오테크놀로지스 아이엔씨. | 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법 |
| CA3069259A1 (en) * | 2017-07-27 | 2019-01-31 | Medi-Immune Limited | Vaccine compositions |
| GB2564901B (en) * | 2017-07-27 | 2020-04-08 | Medi Immune Ltd | Vaccine compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| CA2323733A1 (en) * | 1998-04-13 | 1999-10-21 | Michael B. Brenner | Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof |
| EP0976403A1 (en) * | 1998-07-30 | 2000-02-02 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Adjuvant comprising pulmonary surfactant |
| DE60025019T2 (de) | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
| WO2001075096A1 (en) | 2000-04-04 | 2001-10-11 | Antigenics Inc. | Isolated and purified nonpeptide antigens from mycobacterium tuberculosis |
| MXPA02012501A (es) | 2000-06-16 | 2003-06-06 | Sembiosys Genetics Inc | El uso de cuerpos grasos vegetales en sistemas de administracion de vacunas. |
| GB0021757D0 (en) | 2000-09-04 | 2000-10-18 | Colaco Camilo | Vaccine against microbial pathogens |
| DE10044622A1 (de) * | 2000-09-09 | 2002-03-21 | Krupp Corpoplast Maschb Gmbh | Vorrichtung zur Herstellung von Vorformlingen |
| US20030190333A1 (en) * | 2002-02-04 | 2003-10-09 | Corixa Corporation | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
| GB0401239D0 (en) | 2004-01-21 | 2004-02-25 | Molecularnature Ltd | Adjuvant compositions |
| TWI277032B (en) * | 2004-02-27 | 2007-03-21 | Au Optronics Corp | Planar display module |
| JP2007536273A (ja) | 2004-05-07 | 2007-12-13 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肺マラリアワクチン |
-
2007
- 2007-08-31 CN CNA200780035181XA patent/CN101522213A/zh active Pending
- 2007-08-31 WO PCT/AU2007/001277 patent/WO2008025095A1/en not_active Ceased
- 2007-08-31 AU AU2007291887A patent/AU2007291887B2/en not_active Ceased
- 2007-08-31 EP EP07800235.9A patent/EP2066341B1/en active Active
- 2007-08-31 ES ES07800235.9T patent/ES2547855T3/es active Active
- 2007-08-31 JP JP2009525861A patent/JP5265545B2/ja not_active Expired - Fee Related
- 2007-08-31 US US12/439,054 patent/US9150619B2/en active Active
- 2007-08-31 CA CA002662164A patent/CA2662164A1/en not_active Abandoned
- 2007-08-31 NZ NZ575141A patent/NZ575141A/en not_active IP Right Cessation
- 2007-08-31 DK DK07800235.9T patent/DK2066341T3/en active
- 2007-08-31 KR KR1020097006683A patent/KR20090064412A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2066341B1 (en) | 2015-07-15 |
| JP5265545B2 (ja) | 2013-08-14 |
| WO2008025095A1 (en) | 2008-03-06 |
| EP2066341A1 (en) | 2009-06-10 |
| DK2066341T3 (en) | 2015-10-19 |
| KR20090064412A (ko) | 2009-06-18 |
| JP2010501595A (ja) | 2010-01-21 |
| CN101522213A (zh) | 2009-09-02 |
| EP2066341A4 (en) | 2010-11-10 |
| AU2007291887B2 (en) | 2012-09-27 |
| US9150619B2 (en) | 2015-10-06 |
| US20090324642A1 (en) | 2009-12-31 |
| CA2662164A1 (en) | 2008-03-06 |
| AU2007291887A1 (en) | 2008-03-06 |
| NZ575141A (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11571472B2 (en) | Immunogenic combinations | |
| US20170182148A1 (en) | Immunopotentiator-linked oligomeric influenza immunogenic compositions | |
| ES2488941T3 (es) | Vectores y constructos de liberación de antígenos de virus de la gripe | |
| JP2003509473A (ja) | ワクチン | |
| ES2790527T3 (es) | Composiciones de vacunas contra el síndrome reproductivo y respiratorio porcino y las enfermedades asociadas al circovirus porcino | |
| JP5766894B2 (ja) | ワクチン増強剤としてのαチモシンペプチド | |
| RU2008102930A (ru) | Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки | |
| ES2662022T3 (es) | Vacunas atenuadas de la gripe porcina y procedimientos de fabricación y uso de las mismas | |
| US20160129099A1 (en) | Treatment and prevention of malaria | |
| JP2007525456A (ja) | ウマ２型インフルエンザウイルスのｈａ１を発現するｄｎａワクチン | |
| Lee et al. | A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus | |
| Shin et al. | Effect of zymosan and poly (I: C) adjuvants on responses to microneedle immunization coated with whole inactivated influenza vaccine | |
| JP2020536925A5 (enExample) | ||
| US20240238411A1 (en) | Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations | |
| CA2828068C (en) | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines | |
| Zuckermann et al. | An effective vaccine against influenza A virus based on the matrix protein 2 (M2) | |
| AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
| US20250170236A1 (en) | A novel cationic adjuvant composition | |
| CA3076263C (en) | Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv) | |
| ES2615120T3 (es) | Adyuvantes peptídicos | |
| KR20240052044A (ko) | 코로나바이러스과 바이러스에 의한 감염을 치료 또는 예방하기 위한 바이러스-유사 입자 | |
| WO1998046263A1 (en) | Saponin adjuvants in combination with dna vaccination | |
| WO2013015668A2 (es) | Uso del péptido gk-1 expresado en el fago filamentoso m13 para la elaboración de productos farmacéuticos que aumentan la eficiencia de la respuesta inmune inducida por antígenos vacunales o patógenos | |
| WO2015025068A1 (es) | Vacuna recombinante frente al virus de la septicemia hemorrágica vírica | |
| EP4483898A1 (en) | Intranasal vaccine composition and method for boosting using the same |